Punto funding news – London-based Punto Health Secures €645k in Funding

A number of Business Angels, including a scout from the American fund Sequoia, Bruce Walker (a scout from the British fund Ada Ventures), Gail Armstrong (through the British fund Lavender Ventures), and Branislav Trajkovski, participated in the round in addition to the German fund Heartfelt_ and the Spanish funds Abac Nest and Bolsa Social Fund.

Under the direction of Jack Eckersley and Anna Muñoz Farré, the Punto Health team is creating a comprehensive platform driven by AI to enhance treatment for dementia patients and their families. The platform provides individualised material, such as answers, resources, and recommendations based on clinical validation for each user.

Read also - Iris.ai funding news – Oslo-based Iris.ai Secures €7.64 Million in Funding

It offers care plans, dietary advice, cognitive and physical activity suggestions, and specific resources and support for family members and carers at every stage of the illness. It also features an interactive chatbot that serves as a verified personal assistant and dependable friend.

Anna, founder and CEO of Punto Health said, “We all know someone who has been affected by dementia in one way or another, and it is only growing. By 2030, there will be over 78 million people living with dementia, so it is time to redefine cognitive care models, This investment will accelerate the development of our platform, providing patients and their families with a trusted companion every step of the way.”

Punto Health is verifying a novel digital biomarker that is integrated into its platform in close partnership with Ace Alzheimer Centre, a pioneer in dementia research, diagnosis, and treatment in Europe. This biomarker aids in the early detection and monitoring of the disease at every stage by enabling the assessment of cognitive state using spontaneous speech analysis.

In order to deliver thorough and individualised care, the platform also gives medical personnel access to patient data that is continuously collected. This enables for remote monitoring, early abnormality detection, and clinical decision-making.

Punto Health's overall goals are to enable patients to preserve their independence for as long as possible, lessen the mental and physical strain on family members, and provide medical professionals with cutting-edge resources to maximise treatment and monitoring, all of which will enhance the quality of life for everyone involved.

Joerg Rheinboldt, General Partner of Heartfelt_, commented: “We are thrilled to support Anna, Jack and the Punto Health team in their journey to redefine the early detection and management of dementia with their innovative biomarker approach. Their vision aligns with our commitment to investing in teams that drive meaningful change and deliver outstanding value to end customers.”

Joan Pina, Managing Partner of Abac Nest, added: “At Abac Nest Ventures, we are thrilled to invest in Punto Health, led by the highly skilled team of Anna and Jack. Punto Health impressed us with its unique technology and a business purpose that we quickly connected with: applying technology and AI to improve the quality of life for Alzheimer’s patients, while making management easier for their families and caregivers. This investment reflects our commitment to supporting AI solutions that enhance the quality of life for patients and families dealing with complex diseases.”

José Moncada, Managing Partner of Bolsa Social Fund, said: “As an impact fund, we seek to drive innovative solutions to address major social challenges in a structural way. We believe that Punto Health’s technology will improve the treatment and monitoring of Alzheimer’s and other neurodegenerative diseases, with enormous potential to significantly improve the quality of life for patients, their families, and carers.”

About Punto Health

Punto Health uses an AI-powered platform to connect patients, families, and physicians, enabling ongoing assistance. They offer a reliable companion every step of the journey, from the early discovery of moderate cognitive impairment to more severe stages of dementia.